Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
- Resource Type
- Abstract
- Source
- In
Blood 5 November 2020 136 Supplement 1:1-1 - Subject
- Language
- ISSN
- 0006-4971